Persistent endothelial activation and inflammation after Plasmodium falciparum Infection in Malawian children

Moxon, C. A., Chisala, N. V., Wassmer, S. C., Taylor, T. E., Seydel, K. B., Molyneux, M. E., Faragher, B., Kennedy, N., Toh, C-H., Craig, A. G., & Heyderman, R. S. (2014). Persistent endothelial activation and inflammation after Plasmodium falciparum infection in Malawian children. The Journal of Infectious Diseases, 209(4), 610-615. https://doi.org/10.1093/infdis/jit419

Published in:
The Journal of Infectious Diseases

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Download date: 21. Oct. 2023
Persistent Endothelial Activation and Inflammation After Plasmodium falciparum Infection in Malawian Children

Christopher A. Moxon,1,4,2 Ngawina V. Chisala,1 Samuel C. Wassmer,6 Terrie E. Taylor,2,3 Karl B. Seydel,2,3,7 Malcolm E. Molyneux,4 Brian Faragher,4 Neil Kennedy,3 Cheng-Hock Toh,6 Alister G. Craig,4 and Robert S. Heyderman1,4

1Malawi-Liverpool-Wellcome Clinical Research Programme, 2Blantyre Malaria Project, and 3Department of Paediatrics, Queen Elizabeth Hospital, University of Malawi College of Medicine, Blantyre; 4Liverpool School of Tropical Medicine, and 5Institute of Infection and Global Health, Liverpool University, United Kingdom; 6New York University School of Medicine, New York; and 7College of Osteopathic Medicine, Michigan State University, East Lansing

Endothelial dysregulation is central to the pathogenesis of acute Plasmodium falciparum infection. It has been assumed that this dysregulation resolves rapidly after treatment, but this return to normality has been neither demonstrated nor quantified. We therefore measured a panel of plasma endothelial markers acutely and in convalescence in Malawian children with uncomplicated or cerebral malaria. Evidence of persistent endothelial activation and inflammation, indicated by increased plasma levels of soluble intracellular adhesion molecule 1, angiopoietin 2, and C-reactive protein, were observed at 1 month follow-up visits. These vascular changes may represent a previously unrecognized contributor to ongoing malaria-associated morbidity and mortality.

Keywords. Plasmodium falciparum; pathogen burden; endothelial activation; endothelial dysfunction; inflammation; cardiovascular disease; stroke; pediatric.

Plasmodium falciparum causes approximately 300 million clinical episodes of malaria every year, mainly in sub-Saharan Africa [1]. In hyperendemic regions, children may receive >1 infective bite per day and experience repeated clinical episodes [2]. Although acute infection is directly responsible for 750 000 deaths [3], it is increasingly apparent that there is an additional indirect burden of mortality. Several studies have shown that reducing malaria transmission in a population may be followed by all-cause childhood mortality reductions as high as 70%, a greater effect on mortality than can be attributed to reducing parasitic febrile illness alone [2, 4, 5]. The cause of this additional burden remains uncertain. Given the alteration in vascular endothelial function during acute malaria pathogenesis, 1 plausible mechanism is that endothelial dysfunction persists beyond the acute febrile episode and influences the risk or outcome of reinfection or other diseases.

We postulated that malaria infection induces persistent alteration in endothelial activation. We tested this using a panel of plasma endothelial markers linked to key endothelial functions: soluble ICAM-1 (sICAM-1) and sE-selectin for endothelial activation; angiopoietin 2 (Ang2) for angiogenesis and endothelial quiescence; C-reactive protein (CRP) for inflammation; prothrombin fragment F1 + 2 for a procoagulant state; and soluble thrombomodulin (sTM) for endothelial damage.

METHODS

Recruitment took place at the Queen Elizabeth Central Hospital, Blantyre, Malawi between January 2010 and June 2011. Children aged 1–12 years were recruited into 1 of 4 clinical categories: (1) cerebral malaria (CM) cases, who fulfilled World Health Organization (WHO) diagnostic criteria [6] and had at least 1 feature of malarial retinopathy [7]; (2) children with uncomplicated malaria (UM); (3) children with parasitemic mild febrile illness (MF); and (4) parasitemic healthy controls (HC), recruited from well children attending elective surgery. Children were included in the UM and MF groups if they had an axillary temperature >37.5°C and no features of organ compromise as indicated by WHO criteria [6]. Parasitemia was screened for on admission and in follow-up visits using a combined P. falciparum histidine rich protein and pan-malarial lactate dehydrogenase rapid diagnostic test kit, and in patients in whom both parameters were positive, parasitemia was confirmed on blood smear. In all patient groups, children were excluded if they had evidence of meningitis or severe malnutrition, had WHO stage 4 human immunodeficiency virus infection, or were on antiretroviral therapy. Informed consent was given by the parent or legal guardian of all children enrolled in the study. The study was approved by the College of Medicine.
The endothelial lining of blood vessels has a critical role in the regulation of blood flow, permeability, coagulation, inflammation, and innate and adaptive immunity [8]. A key determinant of endothelial function is the repertoire of surface receptors expressed, and these phenotypes are highly specific for the vascular beds of different organs [8]. Disruption of this surface receptor phenotype is critical in the pathogenesis of many diseases, including bacterial sepsis, cardiovascular disease, inflammatory bowel disease, and malaria [9, 10]. In acute *P. falciparum* malaria, cytokine- and parasite-mediated alteration of endothelial phenotype leads to endothelial dysfunction and a procoagulant state [10, 11]. In turn, the upregulation of several inducible endothelial surface receptors, including E-selectin and ICAM-1, facilitates the cytoadherence of *P. falciparum*-infected red blood cells (iRBCs) [10], a key component of the pathogenesis of CM [12]. It has been assumed that after each infection following iRBC elimination these perturbations resolve quickly and completely, with the endothelium rapidly returning to its predisease state. Here we show that endothelial activation and systemic inflammation persist after iRBCs are cleared from the circulation. This was most pronounced in CM, where CRP remained raised 22-fold higher at 28-day follow-up when compared with the HC group. However, significant inflammation and endothelial activation was also detectible in UM, with CRP remaining 13-fold above that of the HC group at 7-day follow-up and ICAM-1 and Ang2 remaining raised until the 28-day follow-up. This persistence cannot be explained by the half-lives of these factors, because, for example, CRP and Ang2 have half-lives of 19 hours [13] and 18 hours [14], respectively. Persistent endothelial activation was not specific to malaria. In agreement with prior studies indicating persistent endothelial activation after other common infections [15], there was also endothelial activation in the group with mild nonmalarial infections. Nonetheless, the long-term effect of malaria might be anticipated to be particularly important in hyperendemic countries such as Malawi, where the frequency of repeated malaria infections may be sufficient to prevent return to baseline before the next infection (malarial or otherwise). Thus children who live in areas of high malaria transmission may be in a constantly deregulated endothelial state. This may influence outcome for patients in several different ways. First, subacute impairment of endothelial barrier function, as indicated here by increased Ang2, may increase invasion of bacteria or viruses into the blood stream. This mechanism has been proposed to explain the causal association between incidence of malaria and bacteremia shown using epidemiological modeling in Kenya [5]. Second, because endothelial activation is implicated in the pathogenesis of a number of infections, including malaria and bacterial sepsis, acquiring a subsequent infection while the endothelium remains activated may have an endothelial priming effect, increasing the vascular dysfunction and thus the severity of disease. Specifically, because parasites that bind ICAM-1 have been shown to be associated with CM [12], the residual ICAM-1 upregulation, indicated by raised sICAM-1 here, may
vascular risk than any particular pathogen [15]. This indicates that even if the effect from each parasite variants associated with higher incidence of CM. Finally, in the long term, chronic endothelial activation and inflammation may contribute to the endothelial changes that cause cardiovascular disease [15, 16]. In industrialized countries, the number of infectious episodes of common infections a person has accrued over their lifetime—their “pathogen burden”—has been implicated in risk of myocardial infarction in a dose–response fashion and is a better predictor of cardiovascular risk than any particular pathogen [15]. This indicates that although each individual infection may only cause a small residual insult to the vasculature, over multiple infectious episodes this may accumulate to cause severe pathology. Given the very high frequency of new malaria infections in many parts of sub-Saharan Africa, malaria may contribute substantially to this pathogen burden—even if the effect from each infectious episode is small. Although there is a paucity of epidemiological studies investigating the etiology of cardiovascular diseases in sub-Saharan Africa, these diseases are a significant cause of morbidity and mortality [17]. As a higher proportion of the population survives into and past middle age, their prevalence rates are likely to increase. Large epidemiological studies to identify the specific risk factors in Africans are needed, and our

| Characteristic                          | Healthy Controls (n = 36) | Mild Febrile Illness (n = 88) | Uncomplicated Malaria (n = 84) | Cerebral Malaria (n = 18) |
|----------------------------------------|--------------------------|-------------------------------|-------------------------------|--------------------------|
| Age, years, mean (95% CI)             | 4.6 (3.7–5.7)            | 3.2 (2.8–3.6)*               | 4.7 (4.1–5.3)                | 4.1 (3.3–5.2)            |
| Female sex, No. (%)                    | 13 (36)                  | 35 (40)                       | 47 (56)                      | 8 (44)                   |
| Clinical parameters on day 0, mean (95% CI) |                      |                               |                               |                          |
| Axillary temperature                   | 36.6 (36.5–36.7)         | 38.4 (38.2–38.5)**           | 38.5 (38.4–38.7)**           | 39.0 (38.5–39.6)**       |
| Heart rate, beats/minutes              | 109 (104–114)            | 127 (119–135)**              | 130 (124–137)**              | 145 (129–163)**          |
| Systolic blood pressure, mm Hg         | 107 (101–113)            | 114 (110–117)**              | 113 (110–117)*               | 97 (92–102)**            |
| Respiratory rate, breaths/minutes      | 28 (26–30)               | 30 (29–31)                   | 28 (27–29)                   | 46 (42–51)**             |
| Glucose, mmol/L                       | 5.0 (4.8–5.2)            | 5.1 (4.9–5.3)                | 5.7 (5.4–6.0)**              | 5.6 (4.6–6.9)*           |
| Lactate, mmol/L                       | 1.8 (1.7–2.0)            | 1.7 (1.6–1.9)                | 2.3 (2.1–2.5)                | 5.2 (3.9–6.9)**          |
| Hemoglobin, g/L                       | 10.4 (9.9–11.0)          | 10.7 (10.3–11.1)             | 9.0 (8.6–9.4)**              | 6.1 (5.4–7.0)**          |
| Platelets, ×10^9/L                    | 380 (347–416)            | 300 (267–338)*               | 110 (93–131)*****            | 31 (21–46)*****          |
| Parasitemia, parasites ×10^3/µL        | 0                        | 0                             | 20 (9.9–40)                  | 68 (27–171)              |
| HIV* positive, No. (%)                 | 0 (0)                    | 4 (4.8)                      | 3 (3.5)                      | 2 (1.1)                  |
| sICAM-1, pg/mL day 0                   | 196 (160–247)            | 316 (295–339)**              | 464 (295–505)**              | 624 (377–1033)****       |
| sICAM-1, pg/mL day 7                   | (…)                     | 258 (235–282)                | 343 (299–394)**              | 478 (364–626)**          |
| sICAM-1, pg/mL day 28                  | (…)                     | 269 (242–299)**              | 277 (251–304)**              | 291 (201–421)**          |
| sE-selectin, pg/mL day 0               | 68 (57–82)               | 122 (105–142)**              | 147 (130–160)*****           | 205 (158–266)**          |
| sE-selectin, pg/mL day 7               | (…)                     | 76 (66–87)                   | 79 (68–91)                   | 109 (77–154)*            |
| sE-selectin, pg/mL day 28              | (…)                     | 79 (68–92)                   | 82 (74–91)                   | 93 (64–135)              |
| Ang2, pg/mL day 0                      | 232 (207–261)            | 382 (339–431)**              | 579 (523–641)**              | 1536 (1190–1982)****     |
| Ang2, pg/mL day 7                      | (…)                     | 383 (333–440)**              | 442 (389–502)**              | 548 (401–749)**          |
| Ang2, pg/mL day 28                     | (…)                     | 311 (275–350)**              | 320 (285–359)**              | 307 (213–443)            |
| sTM, pg/mL day 0                       | 4.7 (4.2–5.2)            | 4.5 (4.2–4.9)                | 6.0 (5.4–6.5)*               | 9.1 (7.5–11.1)**         |
| sTM, pg/mL day 7                       | (…)                     | 4.7 (4.3–5.1)                | 5.0 (4.4–5.6)                | 5.6 (4.3–7.2)            |
| sTM, pg/mL day 28                      | (…)                     | 5.2 (4.8–5.6)                | 4.6 (4.1–5.3)                | 4.1 (3.4–5.1)            |
| CRP, mg/mL enrollment                  | 0.41 (0.23–0.74)         | 26.7 (20–35)**               | 75 (61–92)**                 | 149 (111–199)**          |
| CRP, mg/mL day 7                       | (…)                     | 3.0 (2.0–4.4)**              | 5.3 (4.2–6.7)**              | 16.0 (8.3–32)**          |
| CRP, mg/mL day 28                      | (…)                     | 0.62 (0.37–1.0)              | 0.73 (0.48–1.1)              | 12.7 (3.1–52)**          |
| F1 + 2, pg/mL day 0                    | 176 (140–220)            | 142 (120–167)                | 219 (180–268)                | 376 (245–577)*           |
| F1 + 2, pg/mL day 7                    | (…)                     | 176 (135–229)                | 220 (196–260)                | 500 (279–898)**          |

For each variable, differences between healthy controls and other patient groups were examined using a Fisher’s exact test (categorical variables) or 1-way analysis of variance (continuous variables) with the Tukey honestly significant difference test to adjust for multiple comparisons. Comparisons were not made for parasitemia or HIV. Abbreviations: Ang2, angiopoetin 2; CI, confidence interval; CRP, C-reactive protein; HIV, human immunodeficiency virus; sICAM-1, soluble intercellular adhesion molecule 1; sTM, soluble thrombomodulin. *P < .05, **P < .01, ***P < .001.

a All mean values are geometric means and their 95% confidence intervals.

b HIV was tested for using rapid testing.
data indicate that malaria should be considered within these future studies.

There are several limitations to this study. First, loss to follow-up of 50% of the patients in each of the groups may have led to bias. Children with UM who attended follow-up had a significantly higher CRP on admission than those who did not attend follow-up (followed-up: mean, 137 mg/mL, 95% confidence interval [CI], 107–166 mg/mL; not followed-up, mean = 71 mg/mL, 95% CI, 50–93 mg/mL; \( P \leq .01 \)), which might indicate that sicker patients were more likely to return to follow-up, leading to an overestimation of the strength of difference with the HC group. However, comparison of all clinical variables...
and all biomarkers among all patients who were followed-up until 28 days with those who were lost to follow-up or excluded did not indicate a systematic bias (data not shown). Second, although the panel of plasma markers used are well validated as indicators of endothelial activation [9], only Ang2 and E-selectin are exclusively produced by the endothelium. In Indonesian adults with malaria, high Ang2 levels predicted impaired endothelial function, measured by endothelium-dependent vasodilation [18]. In that population, these arterial tonometric measurements improved to within normal range by 14 days. It would be interesting to evaluate tonometry in African children to examine whether the raised Ang2 levels at 28 days here are associated with a persistently abnormal vasodilation response. Third, because it was not possible to measure preinfection levels of the biomarkers and we were not able to follow-up this cohort long-term, we have not proven that malaria causes the higher levels of biomarkers described at 28 day follow-up. It is possible, although we think unlikely, that instead patients in the febrile groups had preexisting higher baseline biomarker levels. Finally, because we studied children with symptomatic disease it remains unclear whether there is endothelial activation induced by parasitemia that is not associated with febrile illness, which would have important implications given the frequency of asymptomatic malaria infections.

Further research is needed to clarify the extent and duration of the endothelial perturbations described here and their relevance in other malaria-prevalent countries and to ascertain whether burden of malaria infection is independently associated with adverse outcomes due to endothelial dysfunction in the short or long term. If such studies confirm a chronic effect of repeated vascular insults by malaria infection, that would have important implications: influencing the priority of preinfection interventions to older children and adults in addition to the young children who die from acute illness. A further consideration is the use of adjunctive therapies to prevent residual endothelial effects in individuals with severe malaria or a high burden of infection. A candidate is statins, which have endothelial protective, anti-inflammatory, and anticoagulant effects and prevent cardiovascular disease even in those without hyperlipidemia [16]. In malaria, statins reduce endothelial activation in vitro and reduce neurodevelopmental sequelae after experimental CM in mice [19]. Short courses of statins during acute illness and convalescence could be targeted to individuals with severe disease.

In conclusion, we demonstrate that in uncomplicated and severe malaria significant endothelial activation and inflammation persists for at least 1 month after elimination of iRBCs. Given the huge burden of repeated infection with malaria, this endothelial activation may represent a significant and previously neglected contribution to long-term health that warrants further evaluation for treatment and prevention strategies.

**Supplementary Data**

Supplementary materials are available at The Journal of Infectious Diseases online (http://jid.oxfordjournals.org/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The post materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

**Notes**

**Acknowledgments.** For assistance with the study, we wish to thank Eric Borgstein (Queen Elizabeth Hospital, Blantyre, Malawi); Grace Matimati, Patricia Phula, Simon Ewing, and the Paediatric Research Ward clinical team (Wellcome Trust Clinical Research Programme and Blantyre Malaria Project), and the Department of Paediatrics and Child Health (Queen Elizabeth Hospital, Blantyre, Malawi).

**Financial support.** This work was supported by a Clinical PhD Fellowship from The Wellcome Trust, United Kingdom (88758 to C. A. M.); and by a grant from the NIH (5R01AI034969-14 to T. E. T.). The Malawi-Wellcome Clinical Research Programme is supported by core funding from The Wellcome Trust.

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005; 434:214–7.
2. Snow RW, Marsh K. The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 2002; 52:235–64.
3. Murray CJ, Rosenfeld LC, Lim SS, et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012; 379:413–31.
4. Bhattachari A, Ali AS, Kachur SP, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med 2007; 4:e309.
5. Scott JA, Berkley JA, Mwangi I, et al. Relation between falciparum malaria and bacteremia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet 2011; 378:1316–23.
6. World Health Organization. WHO Expert Committee on Malaria. World Health Organ Tech Rep Ser 2000; 892:i–v, 1–74.
7. Taylor TE, Fu WJ, Carr RA, et al. Differentiating the pathologies of cerebral malaria by postmortem parasite counts. Nat Med 2004; 10:143–5.
8. Aird WC. Endothelial cell heterogeneity. Cold Spring Harb Perspect Med 2012; 2:a006429.
9. Blankenberg S, Barbaux S, Tiret L. Adhesion molecules and atherosclerosis. Atherosclerosis 2003; 170:191–203.
10. Moxon CA, Grau GE, Craig AG. Malaria: modification of the red blood cell and consequences in the human host. Br J Haematol 2011; 154:670–9.
11. Moxon CA, Wassmer SC, Milner DA Jr, et al. Loss of endothelial protein C receptors links coagulation and inflammation to parasite sequestration in cerebral malaria in African children. Blood 2013; 122:842–51.
12. Ochola LB, Siddondo BR, Ocholla H, et al. Specific receptor usage in Plasmodium falciparum cytoadherence is associated with disease outcome. PLoS One 2011; 6:e14741.
13. Vigushin DM, Peps MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993; 91:1351–7.
14. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood 2004; 103:4150–6.
15. Zhu J, Nieto FJ, Horne BD, Anderson JL, Muhlestein JB, Epstein SE. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001; 103:45–51.

614 • JID 2014:209 (15 February) • BRIEF REPORT
16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195–207.

17. Dalal S, Beunza JJ, Volmink J, et al. Non-communicable diseases in sub-Saharan Africa: what we know now. Int J Epidemiol 2011; 40: 885–901.

18. Yeo TW, Lampah DA, Gitawati R, et al. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proc Natl Acad Sci U S A 2008; 105:17097–102.

19. Reis PA, Estato V, da Silva TI, et al. Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria. PLoS Pathog 2012; 8:e1003099.